Know Cancer

or
forgot password

Androgen Receptor Mutations in Hormone Refractory Prostate Cancer


N/A
N/A
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

Androgen Receptor Mutations in Hormone Refractory Prostate Cancer


OBJECTIVES: I. Test the feasibility of obtaining bone marrow specimens in a cooperative
group setting. II. Determine the frequency of bone marrow invasion by prostate cancer cells
in patients with hormone refractory prostate cancer. III. Evaluate the frequency of androgen
receptor (AR) mutations in bone marrow samples in this patient population. IV. Evaluate the
association between AR mutations and clinical outcomes, including survival, and response to
therapy, such as antiandrogen withdrawal. V. Evaluate the impact of prior pelvic
radiotherapy on the ability to obtain informative tissue.

OUTLINE: Blood and a bone marrow biopsy are collected from each patient before the patient
begins treatment on CLB-9480 or CLB-9583. The specimens are analyzed for androgen receptor
mutations. Patients do not receive results of the genetic testing and the results do not
influence the type or duration of treatment.

PROJECTED ACCRUAL: A total of 243 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS: Histologically proven adenocarcinoma of the prostate that is
refractory to hormone therapy Eligible for any prostate cancer chemotherapy protocol, but
have not started treatment Patients who are eligible for anticancer therapy on Protocol
CLB-9480, CLB-9583, CLB-9680, or CLB-9780 are also eligible for this study if they have
not started treatment on those protocols

PATIENT CHARACTERISTICS: Age: Any age Performance status: CALGB 0-2 Life expectancy: See
Disease Characteristics Hematopoietic: See Disease Characteristics Hepatic: See Disease
Characteristics Renal: See Disease Characteristics

PRIOR CONCURRENT THERAPY: See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

Mary-Ellen Taplin, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Massachusetts, Worcester

Authority:

United States: Federal Government

Study ID:

CDR0000065329

NCT ID:

NCT00002924

Start Date:

January 1997

Completion Date:

Related Keywords:

  • Prostate Cancer
  • adenocarcinoma of the prostate
  • recurrent prostate cancer
  • Prostatic Neoplasms

Name

Location

Roswell Park Cancer InstituteBuffalo, New York  14263
Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Vincent T. Lombardi Cancer Research Center, Georgetown UniversityWashington, District of Columbia  20007
Walter Reed Army Medical CenterWashington, District of Columbia  20307-5000
University of Chicago Cancer Research CenterChicago, Illinois  60637
University of Iowa Hospitals and ClinicsIowa City, Iowa  52242
University of Massachusetts Memorial Medical CenterWorcester, Massachusetts  01655
University of Minnesota Cancer CenterMinneapolis, Minnesota  55455
Lineberger Comprehensive Cancer Center, UNCChapel Hill, North Carolina  27599-7295
Duke Comprehensive Cancer CenterDurham, North Carolina  27710
Comprehensive Cancer Center of Wake Forest University Baptist Medical CenterWinston-Salem, North Carolina  27157-1082
Arthur G. James Cancer Hospital - Ohio State UniversityColumbus, Ohio  43210
Medical University of South CarolinaCharleston, South Carolina  29425-0721
Rhode Island HospitalProvidence, Rhode Island  02903
CCOP - Southern Nevada Cancer Research FoundationLas Vegas, Nevada  89106
University of California San Diego Cancer CenterLa Jolla, California  92093-0658
UCSF Cancer Center and Cancer Research InstituteSan Francisco, California  94115-0128
CCOP - Christiana Care Health ServicesWilmington, Delaware  19899
CCOP - Mount Sinai Medical CenterMiami Beach, Florida  33140
Marlene & Stewart Greenebaum Cancer Center, University of MarylandBaltimore, Maryland  21201
Ellis Fischel Cancer Center - ColumbiaColumbia, Missouri  65203
Barnes-Jewish HospitalSaint Louis, Missouri  63110
Norris Cotton Cancer CenterLebanon, New Hampshire  03756
CCOP - North Shore University HospitalManhasset, New York  11030
State University of New York - Upstate Medical UniversitySyracuse, New York  13210
CCOP - Southeast Cancer Control ConsortiumWinston-Salem, North Carolina  27104-4241
University of Tennessee, Memphis Cancer CenterMemphis, Tennessee  38103
MBCCOP - Massey Cancer CenterRichmond, Virginia  23298-0037
Mount Sinai Medical Center, NYNew York, New York  10029
New York Presbyterian Hospital - Cornell CampusNew York, New York  10021
Veterans Affairs Medical Center - BirminghamBirmingham, Alabama  35233
Veterans Affairs Medical Center - White River JunctionWhite River Junction, Vermont  05009
Dana-Farber Cancer InstituteBoston, Massachusetts  02115
St. Barnabas Medical CenterLivingston, New Jersey  07039
North Shore University HospitalManhasset, New York  11030
Veterans Affairs Medical Center - Chicago (Westside Hospital)Chicago, Illinois  60612
Veterans Affairs Medical Center - San FranciscoSan Francisco, California  94121
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.Syracuse, New York  13217
Veterans Affairs Medical Center - MemphisMemphis, Tennessee  38104
Veterans Affairs Medical Center - RichmondRichmond, Virginia  23249
University of Illinois at Chicago Health Sciences CenterChicago, Illinois  60612
Veterans Affairs Medical Center - TogusTogus, Maine  04330
Veterans Affairs Medical Center - MinneapolisMinneapolis, Minnesota  55417
Veterans Affairs Medical Center - Columbia (Truman Memorial)Columbia, Missouri  65201
University of Nebraska Medical CenterOmaha, Nebraska  68198-3330
Veterans Affairs Medical Center - BuffaloBuffalo, New York  14215
Veterans Affairs Medical Center - SyracuseSyracuse, New York  13210
Veterans Affairs Medical Center - DurhamDurham, North Carolina  27705
St. Joseph's Hospital and Medical CenterPaterson, New Jersey  07503